Ingo Mellinghoff

Ingo K. Mellinghoff is a physician-scientist and Professor at Memorial Sloan Kettering Cancer Center (MSKCC), serving as Chair of the Department of Neurology. He leads the Human Oncology & Pathogenesis Program (HOPP) laboratory, focusing on molecular mechanisms of brain tumor growth, particularly gliomas and primary CNS lymphomas. His work bridges experimental models and clinical trials, emphasizing targeted therapies and liquid biopsy applications.

• Affiliations: Brain Tumor Center, Gerstner Sloan Kettering Graduate School

Research interests include IDH mutations, tumor metabolism, microenvironment interactions, and biomarker-driven trials. Notable achievements include advancing vorasidenib (a mutant IDH inhibitor) to phase 3 trials and developing cerebrospinal fluid-based liquid biopsy techniques for glioma monitoring.

Recent articles highlight clinical trial results for IDH inhibitors and translational studies on tumor biology. Awards include the Neuro-Oncology Scientific Award (2023) and membership in prestigious medical societies.